Compare Fiverr International Ltd (FVRR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Viatris Inc — how do they compare? Fiverr International Ltd trades at $8.64 (market cap $314.57M), while Viatris Inc trades at $16.31 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 59.4× Fiverr International Ltd's market cap, and Viatris Inc pays a 2.95% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| FVRR | VTRS | |
|---|---|---|
Market Cap | $314.57M | $18.69B |
Sector | Industrials | Health |
52-Week High | $26.67 | $17.86 |
52-Week Low | $8.75 | $9.49 |
Enterprise Value | $66.95M | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $9.09, down 3.5% amid bearish technical signals and recent earnings misses. The stock shows attractive valuation metrics with P/E of 10.8 and P/S of 0.77, while revenue grew to $430.91M in 2025. However, Q2 2026 results disappointed with revenue declining 10% year-over-year as AI disruption pressures the freelance marketplace business model. Analyst sentiment remains cautious with 76% hold ratings despite a $10.70 consensus price target suggesting 18% upside potential.
Fiverr faces significant headwinds from AI competition compressing demand for lower-value freelance work, though current valuations appear discounted. The company maintains strong gross margins at 82% and positive net income, but growth sustainability concerns persist. Near-term catalysts include Q3 earnings and AI strategy execution, while risks center on market share erosion and guidance revisions. The stock trades near support levels with mixed technical indicators.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
